Literature DB >> 16905701

Treating viral hepatitis C: efficacy, side effects, and complications.

M P Manns1, H Wedemeyer, M Cornberg.   

Abstract

The treatment of hepatitis C has dramatically improved over the past decade. Unlike any other chronic viral infection, a significant proportion of patients with chronic hepatitis C can be cured. However, the current standard therapy--pegylated interferon alpha and ribavirin--has its limitations. Limited efficacy in patients with hepatitis C virus (HCV) genotype 1 and the side effect profile will necessitate the development of new therapeutic approaches. This review describes the efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations. New treatment directions beyond interferon alpha based therapies are on the horizon.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16905701      PMCID： PMC1860034          DOI： 10.1136/gut.2005.076646

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  98 in total

1.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

Authors:  Nezam H Afdhal; Douglas T Dieterich; Paul J Pockros; Eugene R Schiff; Mitchell L Shiffman; Mark S Sulkowski; Teresa Wright; Zobair Younossi; Betty L Goon; K Linda Tang; Peter J Bowers
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

2.  Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.

Authors:  Norbert Bräu; Maribel Rodriguez-Torres; Dale Prokupek; Maurizio Bonacini; Carol A Giffen; Jeffery J Smith; Kevin R Frost; Jay R Kostman
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

3.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

4.  Persistent GB virus C infection and survival in HIV-infected men.

Authors:  Carolyn F Williams; Donna Klinzman; Traci E Yamashita; Jinhua Xiang; Philip M Polgreen; Charles Rinaldo; Chenglong Liu; John Phair; Joseph B Margolick; Dietmar Zdunek; Georg Hess; Jack T Stapleton
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

5.  Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

Authors:  Sanaa M Kamal; Alaa Ismail; Camilla S Graham; Qi He; Jens W Rasenack; Thomas Peters; Ahmed A Tawil; Jutta J Fehr; Khalifa El Sayed Khalifa; Mahmoud M Madwar; Margaret James Koziel
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

Review 6.  Treatment of chronic hepatitis C in patients with decompensated cirrhosis.

Authors:  Gregory T Everson
Journal:  Rev Gastroenterol Disord       Date:  2004

7.  Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

Authors:  Hector Rodriguez-Luna; Amer Khatib; Pratima Sharma; Giovanni De Petris; James W Williams; Jose Ortiz; Kathleen Hansen; David Mulligan; Adyr Moss; David D Douglas; Vijayan Balan; Jorge Rakela; Hugo E Vargas
Journal:  Transplantation       Date:  2004-01-27       Impact factor: 4.939

8.  Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

Authors:  Stefan Zeuzem; Rolf Hultcrantz; Marc Bourliere; Tobias Goeser; Patrick Marcellin; Jose Sanchez-Tapias; Christoph Sarrazin; Joann Harvey; Clifford Brass; Janice Albrecht
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

9.  Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial.

Authors:  Mark S Sulkowski; Franco Felizarta; Cheryl Smith; Jidah Slim; Ruth Berggren; Russell Goodman; Lisa Ball; Mandana Khalili; Douglas T Dieterich
Journal:  J Acquir Immune Defic Syndr       Date:  2004-04-15       Impact factor: 3.731

10.  Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.

Authors:  Jérôme Dumortier; Jean-Yves Scoazec; Philippe Chevallier; Olivier Boillot
Journal:  J Hepatol       Date:  2004-04       Impact factor: 25.083
View more
  223 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Hepatitis C: Enhancing treatment for hepatitis C among drug users.

Authors:  Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-30       Impact factor: 46.802

3.  Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia.

Authors:  Bing Li; Ying Jie Ji; Qing Shao; Zhenyu Zhu; Dong Ji; Fan Li; Guofeng Chen
Journal:  Exp Ther Med       Date:  2015-10-23       Impact factor: 2.447

4.  Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Authors:  Ann D Kwong; Robert S Kauffman; Patricia Hurter; Peter Mueller
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

5.  Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.

Authors:  Youssef K Ahmad; Salwa Tawfeek; Mohamed Sharaf-Eldin; Hassan E Elbatea; Abdelrahman Kobtan; Ferial El-Kalla; Rehab Badawi; Sherief Abd-Elsalam
Journal:  Hosp Pharm       Date:  2017-04

6.  Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.

Authors:  Renzo Scaggiante; Liliana Chemello; Roberto Rinaldi; Giovanni Battista Bartolucci; Andrea Trevisan
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

7.  Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.

Authors:  Julia L Marcus; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Jennifer O Lam; Mary Pat Pauly; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg
Journal:  Public Health Rep       Date:  2018-05-11       Impact factor: 2.792

Review 8.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

Review 9.  Measles Resurgence and Drug Development.

Authors:  Richard K Plemper
Journal:  Curr Opin Virol       Date:  2020-04-01       Impact factor: 7.090

Review 10.  Management strategies for hepatitis C virus infection in children.

Authors:  Suzanne M Davison; Deirdre A Kelly
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.